Solid Biosciences to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB) announced participation in two investor conferences focused on Duchenne muscular dystrophy. Co-Founder and CEO Ilan Ganot, along with Chief Scientific Officer Carl Morris, will hold a fireside chat at the Jefferies Cell and Genetic Medicine Summit on September 30, 2022, at 3:00 PM ET, and at Chardan’s 6th Annual Genetic Medicines Conference on October 4, 2022, at 1:00 PM ET. Live webcasts will be available on the company’s investor relations website, with replays accessible post-event.

CHARLESTOWN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Co-Founder, President and CEO, and Carl Morris, Ph.D., Chief Scientific Officer, will participate at the following two upcoming investor conferences:

• Jefferies Cell and Genetic Medicine Summit – New York, NY
  Fireside chat on Friday, September 30, 2022 at 3:00 PM ET.

• Chardan’s 6th Annual Genetic Medicines Conference – New York, NY
  Fireside chat on Tuesday, October 4, 2022 at 1:00 PM ET.
  

A live webcast of these presentations will be available on the Company’s investor relations website, under the Events page accessible here: https://investors.solidbio.com/news-and-events/events. A replay will be available on the Company's website following the events.

About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our gene therapy candidates, SGT-001 and SGT-003. For more information, please visit www.solidbio.com.

Investor Contacts:
Caitlin Lowie
Solid Biosciences
607-423-3219
Clowie@solidbio.com

David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com

Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com

FAQ

What investor conferences is Solid Biosciences participating in?

Solid Biosciences is participating in the Jefferies Cell and Genetic Medicine Summit on September 30, 2022, and Chardan’s 6th Annual Genetic Medicines Conference on October 4, 2022.

When is Solid Biosciences' fireside chat at Jefferies Summit?

The fireside chat at the Jefferies Cell and Genetic Medicine Summit is scheduled for September 30, 2022, at 3:00 PM ET.

When will the Chardan Genetic Medicines Conference fireside chat take place?

The fireside chat at Chardan’s 6th Annual Genetic Medicines Conference will occur on October 4, 2022, at 1:00 PM ET.

Where can I watch the Solid Biosciences investor conference presentations?

The presentations can be viewed via live webcast on Solid Biosciences' investor relations website under the Events page.

What is the focus of Solid Biosciences?

Solid Biosciences focuses on advancing therapies for Duchenne muscular dystrophy, aiming to correct the underlying mutation with their gene therapy candidates.